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Molecular chaperonesmaypromote cell survival, but how this
process is regulated, especially in cancer, is not well understood.
Using high throughput proteomics screening, we identified the
cell cycle regulator and apoptosis inhibitor survivin as a novel
protein associated with the molecular chaperone Hsp60. Acute
ablation of Hsp60 by small interfering RNA destabilizes the
mitochondrial pool of survivin, inducesmitochondrial dysfunc-
tion, and activates caspase-dependent apoptosis. This response
involves disruption of an Hsp60-p53 complex, which results in
p53 stabilization, increased expression of pro-apoptotic Bax,
and Bax-dependent apoptosis. In vivo, Hsp60 is abundantly
expressed inprimaryhuman tumors, as comparedwithmatched
normal tissues, and small interfering RNA ablation of Hsp60 in
normal cells is well tolerated and does not cause apoptosis.
Therefore, Hsp60 orchestrates a broad cell survival program
centered on stabilization of mitochondrial survivin and
restraining of p53 function, and this process is selectively
exploited in cancer. Hsp60 inhibitors may function as attractive
anticancer agents by differentially inducing apoptosis in tumor
cells.
Molecular chaperones, especially members of the Heat
Shock Protein (Hsp)2 gene family (1), assist in protein folding
quality control, protein degradation, and protein trafficking
among subcellular compartments (2). This involves periodic
cycles of ATPase activity, recruitment of additional chaper-
ones, and compartmentalization in subcellular microdomains,
including mitochondria (3). Molecular chaperones have often
been associated with enhanced cell survival (4) via suppression
of apoptosome-initiated mitochondrial cell death (5),
increased stability of survival effectors (6), and inactivation
of p53 (7). As typically represented by Hsp90, the chaperone
anti-apoptotic function may become selectively exploited in
cancer (8) and may play a central role in tumor cell mainte-
nance (9), but how general this paradigm is for other chap-
erones is not well understood.
In particular, Hsp60, togetherwith its associated chaperonin,
Hsp10, has been recognized as an evolutionarily conserved
stress response chaperone (10), largely but not exclusively com-
partmentalized in mitochondria (11) and with critical roles in
organelle biogenesis and folding/refolding of imported prepro-
teins (12). However, whether Hsp60 also contributes to cell
survival is controversial, with data suggesting a pro-apoptotic
function via enhanced caspase activation (13, 14) or, con-
versely, an anti-apoptotic mechanism involving sequestration
of Bax-containing complexes (15). A role of Hsp60 in cancer is
equally uncertain, as up-regulation (16, 17) or down-regulation
(18, 19) of this chaperone has been reported in various tumor
series correlating with disease outcome.
There is now accumulating evidence that molecular chaper-
ones play a key role in regulating the function of survivin (20),
one of themost “cancer-specific” genes (21) involved in protec-
tion from apoptosis and control of mitosis in transformed cells.
Accordingly, binding of survivin to Hsp90 (22) or the immu-
nophilin aryl hydrocarbon receptor-interacting protein (AIP)
(23)maintains survivin stability against proteasome-dependent
destruction (22, 23) and preserves an anti-apoptotic threshold
in tumor cells (24).
In this study, we used high throughput proteomics screening
to identify novel binding partners of survivin that potentially
contribute to its tumorigenic role. We found that Hsp60 (12)
associates with survivin, and this recognition contributes to a
broad anti-apoptotic program differentially exploited in
tumors in vivo.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—Breast adenocarcinoma cells
MCF-7 and MDA-MB-231, colon adenocarcinoma cells
HCT116, normal intestinal epithelial cells Fhs 74INT, and pri-
mary WS-1 or HFF normal fibroblasts were obtained from the
American Type Culture Collection (Manassas, VA) and main-
tained in culture as recommended by the supplier. Wild-type
(WT), p53/, and Bax/HCT116 cells were kindly provided
by Dr. B. Vogelstein (Johns Hopkins University, Baltimore,
MD). To generate a cell line stably expressing survivin, MCF-7
cells were transfected with survivin cDNA by Lipofectamine
(Invitrogen) and selected in a medium containing 1 mg/ml
G418 (Invitrogen), and the colonies were picked after 2–3
weeks. Transfected clones were expanded and confirmed for
overexpression of survivin (3–4-fold over endogenous lev-
els) by Western blotting. Antibodies against Hsp60 (BD
Transduction Laboratories), survivin (NOVUS Biologicals),
p53 (Oncogene Research Products and Santa Cruz Biotech-
nology), p21 (Oncogene), Bax (Oncogene), Mdm-2 (Santa
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Cruz), cleaved caspase-3 (Cell Signaling Technology), -ac-
tin (BD Transduction Laboratories), and Hsp27 (Cell Signal-
ing) were used.
Proteomics Screening—MCF-7 cells were lysed in 25 mM
HEPES, pH 7.5, 100 mM KCl, 1% Triton X-100, plus protease
inhibitors (Roche Applied Science) for 30 min at 4 °C. The cell
extract was precleared with glutathione-agarose beads (Sigma-
Aldrich) for 4 h at 4 °C,mixedwithGST orGST-survivin beads,
and washed with a 20-bead volume of phosphate-buffered
saline, and bound proteins were eluted in 20 mM Tris, pH 7.4, 2
mM EDTA, 0.1% CHAPS, and 1 M NaCl. After concentration
with a ProteoExtract protein precipitation kit (Calbiochem),
sampleswere separated by two-dimensional gel electrophoresis
and visualized by silver staining (Genomine, Pohang, Kyung-
buk, South Korea). Gel image analysis was performed using
PDQuest software (Bio-Rad), and images obtained fromGSTor
GST-survivin eluates werematched after normalization of spot
intensities. Spots detected in the GST-survivin eluate were
excised from the gel and digested with trypsin (Promega), and
peptides were analyzed using an Ettanmatrix-assisted laser de-
sorption ionization time-of-flight system (Amersham). Candi-
date sequences were matched to the Swiss Protein and NCBI
data bases using ProFound.
Transfections—Gene silencing by small interfering RNA
(siRNA) was carried out by transfection of non-targeted or
Hsp60-directed double-stranded RNA oligonucleotides using
Oligofectamine (3l/well) as described (25). Alternatively, cells
were transfected with control or SMARTpool siRNA oligonu-
cleotides toHsp60 (Dharmacon) byOligofectamine. For double
transfection experiments, cells were
loaded twice with control or Hsp60-
directed siRNA at 48-h intervals
between each transfection.
Mitochondrial Import Assay—
The import of recombinant survivin
in purified mitochondria was car-
ried out as described (3). Briefly, ali-
quots of 35S-labeled in vitro tran-
scribed and translated survivin
(TNT system, Promega) were
diluted with 1 volume of MC buffer
containing sucrose (500 mM
sucrose, 80 mM potassium acetate,
20 mM HEPES-KOH, pH 7.5, 5 mM
magnesium acetate) and mixed in a
total volume of 50 l with purified
mouse brain mitochondria (30 g)
for 1 h at 30 °C in the presence or
absence of increasing concentra-
tions of unlabeled survivin. At the
end of the incubation reaction,
mitochondria were reisolated by
centrifugation at 6,000  g for 10
min, and the differential protein
accumulation in mitochondria was
determined by autoradiography.
Analysis of Apoptosis—Trans-
fected cells were harvested after
48 h and stained with a fluorescein-conjugated caspase inhibi-
tor (carboxyfluorescein (FAM)-DEVD-fluoromethyl ketone)
and propidium iodide (CaspaTag, Intergen) for simultaneous
detection of DEVDase (caspase) activity and loss of plasma
membrane integrity by multiparametric flow cytometry as
described (26). Data were analyzed using FlowJo software. To
quantify mitochondrial membrane potential, transfected cells
were loadedwith the fluorescent dye JC-1 (10g/ml;Molecular
Probes) and analyzed for changes in red-green (FL-2/FL-1) flu-
orescence ratio by flow cytometry. Cells treated with CCCP (50
M, for 5 min) served as a positive control.
Subcellular Fractionation—Mitochondrial and cytosolic
fractions were extracted from tumor cells (6–7  107) as
described (27).
Pulldown and Immunoprecipitation—Purified GST fusion
proteins (5 g) were mixed with mitochondrial extracts from
MCF-7 or HCT116 cells, and bound proteins were analyzed by
Western blotting as described (22). Alternatively, 35S-labeled
survivin or 35S-labeled Hsp60 was mixed with GST, GST-
Hsp60, or GST-survivin, and bound proteins were detected by
autoradiography. For immunoprecipitation, cytosolic or mito-
chondrial extracts from HCT116 or MCF-7 cells were incu-
bated with IgG or an antibody to survivin or p53, and the
immune complexeswere precipitated by the addition of protein
A-Sepharose beads (AmershamBiosciences) in 50mMTris, pH
7.5, 0.1% deoxycholate, 1% Nonidet P-40, 0.1% SDS, 50 mM
NaCl, 1 mM protease inhibitors (Roche Applied Science), and 1
mM Na3Vo4. After washing, pellets or supernatants were sepa-
FIGURE 1. Survivin-Hsp60 interaction.A, high throughput proteomics screening for survivin-associatedmol-
ecules. Extracts from MCF-7 cells were fractionated over GST or GST-survivin beads, and protein bands selec-
tively associated with GST-survivin were separated by high-resolution two-dimensional gel electrophoresis
(left panel). A candidate survivin-associatedproteinwas identifiedbymass spectrometry asHsp60 (right panel).
B, pulldown. GST, GST-survivin (Surv) (left panel), or GST-Hsp60 (right panel) was incubated with 35S-labeled in
vitro transcribed and translated Hsp60 or 35S-labeled survivin or hemagglutinin-survivin (HA-Surv), respec-
tively, and bound proteins were analyzed by autoradiography. C, immunoprecipitation. Isolated cytosol (Cyt)
ormitochondrial (Mito) extractswere immunoprecipitated (IP)with IgGor anantibody to survivin, and immune
complexes were analyzed by Western blotting. *, nonspecific.
Hsp60-mediated Cell Survival
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rated by SDS-gel electrophoresis and analyzed by Western
blotting.
Gene Profiling—Relative levels of Hsp60 transcripts in vari-
ous patient cohorts with diagnoses of adenocarcinoma of colon
(28), lung (29), prostate (30), glioblastoma multiformis (31), or
their matched normal tissues were analyzed using Oncomine
(32) and normalized as follows. Log2was transformed, the array
median was set to 0, the array standard deviation was set to 1,
the mean was centered per study, and these were plotted as
normalized expression units.
Immunohistochemistry—Primary tissue specimens of breast,
lung, and colon adenocarcinoma or matched normal tissues
were obtained anonymously from the University of Massachu-
settsCancerCenter tissue bank. Tissue sectionswere processed
for immunohistochemistry using IgG or an antibody to Hsp60
(1:1000) as described (27).
RESULTS
Hsp60 Is a Novel Survivin-associated Molecule—To identify
novel proteins that bind survivin, we used high throughput pro-
teomics screening with fractionation of MCF-7 cell extracts
overGST-survivin and identification of bound proteins by two-
dimensional gel electrophoresis and mass spectrometry (Fig.
1A, left panel). A protein spot with an apparent molecular mass
of 69.6 kDa and a pI of 5.05 was detected in eluates of GST-
survivin, but not GST (right panel), and identified as Hsp60 by
mass spectrometry of the following matched peptide sequenc-
es: GANPVEIRR, GIIDPTKVVR, TVIIEQSWGSPK, GYISPY-
FINTSK, AAVEEGIVLGGGCALLR, and TLNDELEIIEGMK-
FDR (13% total protein coverage). In pulldown experiments,
GST-survivin associated with 35S-labeled in vitro transcribed
and translatedHsp60, whereas GSTwas ineffective (Fig. 1B, left
panel). Reciprocally, 35S-labeled survivin with or without a
hemagglutinin tag associated with GST-Hsp60 but not GST
(right panel). In addition, survivin immunoprecipitated from
mitochondrial, but not cytosolic, extracts contained co-associ-
ated Hsp60 in vivo, whereas immune complexes precipitated
with IgG from either subcellular compartment did not associ-
ate with Hsp60 or survivin (Fig. 1C).
Hsp60 Regulation of Survivin Stability—Single or double
transfection of MCF-7 cells with non-targeted siRNA had no
effect on Hsp60 or survivin levels (Fig. 2A). Conversely, trans-
fection of tumor cells with a single or pool siRNA oligonucleo-
tide toHsp60 resulted in significant reduction ofHsp60 expres-
sion (Fig. 2A). This was associated with concomitant loss of
survivin levels, in a reaction that was maximal in MCF-7 cells
doubly transfected with siRNA to Hsp60 (Fig. 2A). In control
experiments, Hsp60-directed siRNA had no effect on the
expression of an unrelated chaperone, Hsp27 (Fig. 2B), whereas
it reduced Hs60 levels in both its mitochondrial and non-mito-
chondrial (11) compartments (Fig. 2C). All subsequent experi-
ments of Hsp60 knockdown were carried out with a single
transfection of siRNA oligonucleotide. To determine the basis
of survivin decrease after Hsp60 knockdown, we performed
cycloheximide block experiments. Hsp60 knockdown under
these conditions resulted in rapid destabilization and acceler-
ated destruction of survivin protein, as compared with control
cultures transfected with non-targeted siRNA (Fig. 2D).
Hsp60 Targeting Induces Mitochondrial Apoptosis—Trans-
fection of MCF-7 orWTHCT116 cells with control siRNA did
not result in DEVDase, i.e. caspase, activity or a significant
decrease in cell viability measured by multiparametric flow
cytometry, as compared with non-transfected cultures (Fig.
3A). In contrast, acute knockdown of Hsp60 in tumor cell lines
caused loss of plasma membrane integrity and increased
caspase activity (Fig. 3A). In addition, Hsp60 knockdown in
tumor cells resulted in homogenous loss of mitochondrial
membrane potential (Fig. 3C), discharge ofmitochondrial cyto-
chrome c in the cytosol (Fig. 3D), and proteolytic processing of
effector caspase-3 to active fragments of 17 and 19 kDa (Fig.
3E). In control experiments, non-targeted siRNA had no effect
on mitochondrial integrity or procaspase-3 cleavage in MCF-7
cells (Fig. 3, C–E). To determine whether loss of survivin after
Hsp60 knockdown contributed to this cell death response, we
generated MCF-7 clones stably transfected to express survivin
(Fig. 3B,MCF-7 SVV). Hsp60 knockdown in these cells did not
induce caspase activity or loss of plasmamembrane integrity, as
compared with transfected parental MCF-7 cells (Fig. 3A, bot-
tom panel).
Hsp60 Regulation of Mitochondrial Survivin—A pool of sur-
vivin localized to mitochondria is specifically earmarked to
FIGURE 2. Hsp60 regulation of survivin stability. A, siRNA transfection.
MCF-7 cellswere transfectedonce (single) or twice (double)with control (Ctrl)
non-targeted siRNA, a single oligonucleotide directed to Hsp60, or an oligo-
nucleotide pool to Hsp60 (Hsp60-P) and analyzed byWestern blotting. None,
non-transfected cells. B, specificity of siRNA knockdown. MCF-7 cells trans-
fected with the indicated siRNA were analyzed by Western blotting. C, sub-
cellular fractionation. MCF-7 cells were transfected with the indicated siRNA,
fractionated in cytosol (Cyto) or mitochondrial (Mito) extracts, and analyzed
by Western blotting. Bottom panel, densitometric quantification of -actin-
normalized protein bands in cytosol or mitochondria extracts. Cox-IV and
-actin were the mitochondrial and cytosolic markers, respectively. D, cyclo-
heximide (CHX) block. MCF-7 cells were transfected with non-targeted or
Hsp60-directed siRNA, treated with cycloheximide, and analyzed byWestern
blotting (top panel) at the indicated time intervals. Bottompanel, densitomet-
ric quantification of -actin-normalized survivin protein bands in transfected
cells.
Hsp60-mediated Cell Survival
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inhibit apoptosis, and this mecha-
nism enhances tumor growth in
vivo (33). To determinewhether cell
death induced by Hsp60 knock-
down involved the mitochondrial
pool of survivin, we first carried out
mitochondrial import studies in
vitro. 35S-Labeled survivin was
readily imported in isolated mouse
brain mitochondria in a reaction
progressively out-competed by
excess unlabeled survivin (Fig. 4A).
Analysis of isolated subcellular frac-
tions revealed that Hsp60 knock-
down resulted in a nearly complete
loss of mitochondrial survivin lev-
els, whereas the cytosolic pool of
survivin was largely unaffected (Fig.
4B). In these experiments, acute
ablation ofHsp60 by siRNAwas also
associated with increased expres-
sion of p53 in both cytosol andmito-
chondrial extracts, as compared
with non-targeted siRNA (Fig. 4B).
Because some Hsp molecules have
been shown to regulate p53 (34, 35),
next we further investigated poten-
tialmodulation of p53 expression by
Hsp60. siRNA silencing of Hsp60 in
WT HCT116 cells resulted in
increased expression of p53 and
in parallel up-regulation of p53-re-
sponsive genes, Bax, and, to a lesser
extent, p21 (Fig. 4C). In contrast, no
changes in Bax expression were
observed in p53/ HCT116 cells
transfected with control or Hsp60-
directed siRNA (Fig. 4C).
Hsp60 Knockdown Induces p53-dependent Apoptosis—At
variance with cells carrying WT p53, transfection of p53/
HCT116 or p53 mutant MDA-MB-231 cells with Hsp60-di-
rected siRNA did not result in caspase-dependent cell death or
loss of plasmamembrane integrity, as comparedwith untreated
cultures or cells transfected with non-targeted siRNA (Fig. 5A).
Tomap the potential requirement of p53 for cell death induced
byHsp60 knockdown, we next analyzedHCT116 cells deficient
in Bax, a p53 target gene up-regulated by Hsp60 siRNA treat-
ment. In these experiments, transfection of Bax/ HCT116
cells withHsp60-directed siRNAhadno effect on caspase activ-
ity or plasmamembrane integrity (Fig. 5B) and did not result in
loss of mitochondrial membrane potential (Fig. 5C). A control,
non-targeted siRNA did not affect cell viability or mitochon-
drial integrity of Bax/ HCT116 cells (Fig. 5, B and C).
Identification of Hsp60-p53 Complexes—We next asked
whether Hsp60 physically associated with p53, thus potentially
restraining its function. In pulldown experiments, GST-Hsp60,
but notGSTalone, associatedwith p53 in extracts isolated from
WTHCT116 cells (Fig. 6A). In addition, p53 that was immuno-
FIGURE 3. Hsp60 knockdown induces mitochondrial apoptosis. A, caspase activity. WT HCT116, MCF-7, or
MCF-7 cells stably expressing survivin (MCF-7 SVV) were transfectedwith the indicated siRNA and analyzed for
DEVDase (caspase) activity (green fluorescence) and propidium iodide (red fluorescence) staining by multipa-
rametric flow cytometry. None, non-transfected cells. For A and C, the percentage of cells in each quadrant is
indicated. B, characterization of survivin-expressing MCF-7 cells. Parental MCF-7 cells or MCF-7 cells stably
transfected with a survivin cDNAwere analyzed byWestern blotting. C, mitochondrial membrane depolariza-
tion. JC1-loadedMCF-7 cells were transfectedwith the indicated siRNA and analyzed for changes in red-green
fluorescence ratio by flow cytometry. CCCPwas used as a control formitochondrialmembrane depolarization.
D, cytochrome c (Cyto c) release. Tumor cell types were transfected with the indicated siRNA and analyzed by
Western blotting. Ctrl, control. E, active caspase-3 (Casp.3) generation. MCF-7 cells transfected with the indi-
cated siRNA were analyzed by Western blotting.
FIGURE 4. Regulation of mitochondrial survivin and p53 expression by
Hsp60. A, mitochondrial import of survivin. 35S-Labeled survivin was incu-
batedwithmouse brainmitochondria in the presence or absence of the indi-
cated concentrations of unlabeled survivin, and radioactivity associatedwith
mitochondria was determined by autoradiography. Inp, input. B, regulation
of mitochondrial survivin stability by Hsp60. MCF-7 cells transfected with the
indicated siRNA were fractionated in cytosol or mitochondrial (Mito) extracts
and analyzedbyWesternblotting. Cox-IV and-actinwere themitochondrial
and cytosolicmarkers, respectively.Ctrl, control.C, p53 stabilization byHsp60
knockdown. WT or p53/ HCT116 cells were transfected with the indicated
siRNA and analyzed by Western blotting.
Hsp60-mediated Cell Survival
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precipitated from cytosol or mitochondrial extracts of WT
HCT116 cells contained co-associated Hsp60 (Fig. 6B). In con-
trast, control immune complexes that were precipitated with
IgG did not contain Hsp60 (Fig. 6B). We next looked at poten-
tial changes in the expression of the p53 negative regulator,
Mdm-2, in transfected cells. Transfection of MCF-7 or WT
HCT116 cells with Hsp60-directed siRNA did not significantly
affect Mdm-2 levels, as compared with control cultures trans-
fected with non-targeted siRNA (Fig. 6C).
Selective Hsp60 Cytoprotection in Tumors—To determine
whether Hsp60 cytoprotection was preferentially exploited in
cancer, we next examined its expression and function in normal
versus tumor cell types. Hsp60 was abundantly present inmito-
chondrial and extramitochondrial (11), i.e. cytosolic, fractions
of MCF-7 and HCT116 cells (Fig. 7A, left panel). In contrast,
primary WS-1 and HFF human fibroblasts exhibited consider-
ably reduced levels of Hsp60 in both subcellular compartments
(right panel). By immunohistochemistry, Hsp60 was undetect-
able or expressed at very low levels in normal epithelium of
breast, colon, and lung in vivo (Fig. 7B). In contrast, Hsp60 was
abundantly expressed in the tumor cell population of adenocar-
cinomas of the breast, colon, and lung (Fig. 7B). In control
experiments, IgG did not stain normal or tumor epithelia (data
not shown). Consistent with these data, meta-analysis of pub-
lished microarray data sets revealed that Hsp60 expression was
considerably up-regulated in patient samples of adenocarci-
noma of colon, lung, prostate, and glioblastomamultiformis, as
comparedwithmatched normal tissues (Fig. 7C). To determine
whether Hsp60 cytoprotection was selectively operative in
tumor cells, we next targeted Hsp60 expression in normal cell
types and analyzed cell viability. Transfection of 74INT normal
human epithelial cells orWS-1 primary human fibroblasts with
Hsp60-directed siRNA suppressed Hsp60 expression, whereas
a non-targeted siRNA was without effect (data not shown). At
variance with the results obtained with tumor cell lines, acute
siRNA ablation of Hsp60 in normal cells did not result in loss of
cell viability or increased caspase activity, as compared with
control cultures transfectedwith non-targeted siRNA (Fig. 7D).
DISCUSSION
In this study we have shown that the molecular chaperone
Hsp60 (12) is prominently up-regulated in human cancers in
vivo and orchestrates a cytoprotective pathway centered on sta-
bilization of survivin levels and restraint of p53 function (Fig. 8).
Conversely, acute ablation of Hsp60 results in loss of the mito-
chondrial pool of survivin, which is specifically earmarked to
inhibit apoptosis (33), parallel increased expression of p53, and
activation of p53-dependent apoptosis in tumor cells (Fig. 8).
This dual cytoprotective mechanism of Hsp60 is selectively
exploited in tumors in vivo, where Hsp60 is differentially up-
regulated, as compared with normal tissues, and loss of Hsp60
in normal cells is not associated with mitochondrial dysfunc-
tion or cell death.
Although survivin is recognized as a pivotal cancer gene with
dual roles in cell division and inhibition of apoptosis (36, 37),
the molecular requirements of how survivin contributes to
tumorigenesis have not been completely elucidated.However, a
critical requirement of this process is the presence of a pool of
survivin compartmentalized in mitochondria, preferentially in
tumor cells, and released in the cytosol in response to cell death
stimuli (27). There is now evidence that mitochondrial survivin
provides for a pool of the molecule specifically earmarked to
inhibit apoptosis (27, 38), thus directly accelerating tumor
growth in vivo (27), and that this pathway is regulated by com-
partmentalized phosphorylation and differential binding to the
anti-apoptotic cofactor XIAP (X chromosome-linked inhibitor
of apoptosis) (33). Despite the lack of a cleavable, amino-termi-
nal mitochondrial import sequence, we have shown here that
survivin is actively imported in isolated mitochondria. This
pathway may be contributed by molecular chaperones known
to associate with survivin in the cytosol, including Hsp90 (22)
and/or AIP (23), molecules that have been implicated in mito-
chondrial preprotein import (3, 39).Once inmitochondria, sur-
FIGURE 5. p53-dependent apoptosis induced by Hsp60 knockdown.
A, analysis of apoptosis. p53/ HCT116 or p53 mutant MDA-MB-231 cells
were transfected with the indicated siRNA and analyzed for DEVDase activity
and propidium iodide staining by multiparametric flow cytometry. None,
non-transfected cells. For all panels, thepercentageof cells in eachquadrant is
indicated. B andC, requirement of Bax inHsp60 knockdown-induced apopto-
sis. Bax/ HCT116 cells were transfected with the indicated siRNA and ana-
lyzed for DEVDase activity and propidium iodide staining (B) or JC1-sensitive
mitochondrial membrane depolarization (C) by flow cytometry. CCCP was
used as a control for membrane depolarization.
FIGURE 6.Hsp-60-p53 complexes. A, pulldown. GST or GST-Hsp60was incu-
bated with HCT116 extracts, and bound proteins were analyzed by Western
blotting. B, immunoprecipitation. Isolated cytosolic (Cyto) or mitochondrial
(Mito) fractions from HCT116 cells were immunoprecipitated with IgG or an
antibody to p53, and proteins in pellets or supernatants (sup) were analyzed
by Western blotting. C, Mdm-2 expression. MCF-7 or WT HCT116 cells were
transfected with non-targeted or Hsp60-directed siRNA and analyzed by
Western blotting. Ctrl, control.
Hsp60-mediated Cell Survival
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vivin may require the formation of a complex with Hsp60 (12)
to restore optimal refolding after translocation across themito-
chondrialmembrane, a step that involves transient unfolding of
imported proteins (40). Consistent with this model, we have
shown here that siRNA ablation of Hsp60 results in destabili-
zation of survivin levels and nearly complete and selective loss
of the mitochondrial pool of survivin (27, 38), thus abrogating
this anti-apoptotic response (33).
In addition to stabilization of mitochondrial survivin, a sec-
ond mechanism of Hsp60 cytoprotection identified here was
the formation of Hsp60-p53 complexes, which inhibited p53
function in tumor cells. There is precedence for the role of
molecular chaperones in physically restraining p53 function.
Reminiscent of themodel presented
here, mitochondrial Hsp70, also
called mortalin, has been shown to
bind and sequester p53 in the
cytosol (34, 41), thus preventing its
nuclear import, and in centrosomes
(42), where this interaction over-
rides a p53-dependent checkpoint
of centrosomal duplication. Hsp60
regulation of p53 does not appear to
involve changes in the p53 regulator
Mdm-2 and thus is distinct from the
role of inducible Hsp70 in antago-
nizing p53-dependent senescence
(35). Finally, although a mitochon-
drial pool of p53 has been described
that promotes apoptosis via modu-
lation of Bcl-2 family proteins (43),
and loss of Hsp60 resulted in
increased expression of p53 inmito-
chondria, the data presented here
implicate that de novo p53-depend-
ent transcription, i.e. Bax induction,
is required for apoptosis initiated by
Hsp60 targeting.
Given their interface with multi-
ple pathways of tumor maintenance
(8) and their frequent overexpres-
sion in cancer in vivo, molecular
chaperones have been vigorously
pursued for novel cancer therapeu-
tics (9). Taken together (4), the data
presented here suggest that cyto-
protection may be a general prop-
erty of multiple molecular chaper-
ones, including Hsp60, aimed at
elevating an anti-apoptotic thresh-
old in tumor cells in vivo. Intrigu-
ingly, this process appears to be
exploited selectively in transformed
cells but not in normal tissues. In
addition to a sharp differential
expression of these chaperones, i.e.
Hsp60, in cancer as opposed to nor-
mal tissues in vivo, other functional
factors may contribute to the preferential utilization of this
pathway in tumor cells. These may include qualitative changes
in chaperone activity, as has been demonstrated for Hsp90
ATPase function (44), or association with cancer genes differ-
entially expressed in cancer, as is the case for functional sur-
vivin-chaperone complexes (22, 23). Although chaperone-di-
rected cytoprotection may promote tumor cell survival and
favor drug resistance, the differential expression and/or func-
tional exploitation of this pathway in tumor cells may be desir-
able for broader, chaperone-directed anticancer strategies. Val-
idating this concept, molecular or pharmacologic targeting of
complexes between survivin and Hsp90 (24), mortalin and p53
(45), and Hsp60 and survivin/p53 (this work) has been consis-
FIGURE 7.Differential Hsp60 expression and function in tumor cells. A, comparative analysis of normal
and tumor cells. Isolated cytosolic (C) ormitochondrial (M) fractions fromMCF-7 or HCT116 cells (left panel)
or primary WS-1 or HFF normal human fibroblasts (right panel) were analyzed by Western blotting.
B, immunohistochemistry. Primary human tissue specimens of adenocarcinoma of breast, colon, or lung
(Tumor) or matched normal tissues (Normal) were stained with an antibody to Hsp60 and analyzed by
immunohistochemistry. Magnification, 200. C, gene profiling. Microarray data sets of samples (number
of cases are in parentheses) of human adenocarcinoma (AdCa) of colon (28), lung (29), prostate (30),
glioblastomamultiformis (31), or matched normal tissues were analyzed using Oncomine. The p values for
differences in Hsp60 mRNA expression between tumor and normal samples are 1.6E6 (colon), 1.9E8
(lung), 7.6E9 (prostate), and 8.7E13 (glioblastoma multiformis). Data are shown as boxplots, where
whiskers are the minimum and maximum, and boxes are the upper and lower quartiles. D, differential
sensitivity of normal cells to Hsp60 knockdown. 74INT normal epithelial cells or primary WS-1 normal
fibroblasts were transfected with the indicated siRNA and analyzed by DEVDase activity and propidium
iodide staining by multiparametric flow cytometry. The percentage of cells in each quadrant is indicated.
None, non-transfected cells.
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tently associated with selective induction of mitochondrial cell
death in tumor cells without affecting normal cell types, includ-
ing hematopoietic progenitor cells (24).
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FIGURE 8.Model ofHsp60-regulated cytoprotection in cancer. Regulation
of mitochondrial survivin (SVV) stability and p53 expression by Hsp60-con-
taining protein complexes in mitochondria and cytosol. See “Discussion” for
additional details.
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